跳至主要内容
临床试验/IRCT201410161213N3
IRCT201410161213N3已完成未知

Evaluation of short term protective effect of aggressive hydration therapy with lactated ringer’s solution on pancreatitis after endoscopic retrograde cholangiopancreatography

Vice-chancellor for research -Tabriz University of Medical Science0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 70 years(—)
性别
All

入选标准

  • (Indication of endoscopic retrograde cholangiopancreaticography; consent of enrollment in study and Exclusion criteria:Acute cholangitis; sepsis; pregnancy; age above 70 years; chronic pancreatitis; acute pancreatitis due to billiary stone; risk of fluid overload; peripheral edema; pulmonary edema; electrolyte disturbance for example Na over 150 or below 130; history of endoscopic retrograde cholangiopancreaticography performation with sphinctrotomy.)

排除标准

  • 未提供

研究者

发起方
Vice-chancellor for research -Tabriz University of Medical Science

相似试验

未知
3 期
A study to investigate the preventive effect of AG-1749 against the onset of gastric and duodenal ulcers that can be seen during long-term treatment with low dose aspirin.
JPRN-jRCT2080220484Takeda Pharmaceutical Company Limited812
未知
3 期
A study to investigate the preventive effect of AG-1749 against the onset of gastric and duodenal ulcers that can be seen during long-term treatment with nonsteroidal anti-inflammatory drugs (NSAID).
JPRN-jRCT2080220485Takeda Pharmaceutical Company Limited602
进行中(未招募)
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.MedDRA version: 11.0Level: LLTClassification code 10057840Term: <Manually entered code. Term in E.1.1>Major Depressive Disorder
EUCTR2008-004642-92-HUInstitut de Recherches Internationales Servier400
进行中(未招募)
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder. A randomised, double blind, international multicentre study with parallel groups versus duloxetine (60 mg/day). Twenty-four weeks of treatment. - NDMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive Disorder
EUCTR2008-004642-92-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER400
进行中(未招募)
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.Major Depressive Disorder
EUCTR2008-004642-92-PTInstitut de Recherches Internationales Servier400